• Molecules and Cells
• /
• v.20 no.3
• /
• pp.442-445
• /
• 2005

HP0894 (SwissProt/TrEMBL ID O25554) is an 88-residue conserved hypothetical protein from Helicobacter pylori strain 26695 with a calculated pI of 8.5 and a molecular weight of 10.38 kDa. Proteins with sequence similarity to HP0894 exist in Vibrio choierae, Enterococcus faecalis, Campylobacter jejuni, Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli O157, etc. Here we report the sequence-specific backbone resonance assignments of HP0894. About 97.5% (418/429) of the HN, N, CO, $C{\alpha}$, $C{\beta}$ resonances of the 88 residues of HP0894 were assigned. On the basis of these assignments, three helical regions and four strand regions were identified using the CSI program. This study is a prerequisite for calculating the solution structure of HP0894, and studying its interaction with its substrates, if any, and/or with other proteins.

• Pediatric Infection and Vaccine
• /
• v.16 no.1
• /
• pp.13-23
• /
• 2009

Acute otitis media (AOM) and pneumonia are among the most common infectious diseases of children. Both are mucosal infections and share many common features such as etiological agents, pathogenesis and immunity. Influenza plays an important role in the pathogenesis of AOM and pneumonia. A vaccine against influenza may have substantial impact on these diseases during the influenza season. In clinical trials, influenza vaccine has reduced the incidence of AOM and pneumonia complicating influenza in children. However, the efficacy of vaccines has been controversial in children less than 2 years of age. Similarly, vaccines against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib), both common causes of AOM and pneumonia, have the potential to reduce the impact of disease. Clinical trials showed that the currently licensed 7-valent pneumococcal conjugate vaccine (PCV), administered during infancy, had an efficacy of 6-7% for the prevention of AOM, however, visits to the clinic for AOM were reduced by up to 20-30% after routine use in the U.S. Both Hib and PCVs have a proven effectiveness of >20% for prevention of radiologically confirmed pneumonia in children. The recently introduced pnuemococcal vaccine conjugated with protein D is expected to reduce AOM and pneumonia caused by non-typable H. influenzae, in addition to its effects on pneumococcal diseases. Considering their high incidence in children, recent achievements in the prevention of AOM and pneumonia with vaccines may have a significant economic and social impact.

• Biodesign
• /
• v.6 no.4
• /
• pp.96-99
• /
• 2018

The gram-positive bacterium Staphylococcus aureus is a common cause of abscesses, sinusitis and food poisoning. The emergence of antibiotic-resistant strains has caused significant clinical issues worldwide. The HslU-HslV complex was first identified as a prokaryotic homolog of eukaryotic proteasomes. HslU is an unfoldase that mediates the unfolding of the substrate proteins, and it works with the protease HslV in the complex. To date, the protein complex has been mostly studied in gram-negative bacteria. In this study, we report the purification and crystallization of the full-length HslU from S. aureus. The crystal diffracted X-rays to a $3.5{\AA}$ resolution, revealing that the crystals belong to space group $P2_1$, with unit cell parameters of a = 166.5, b = 189.6, $c=226.6{\AA}$, and ${\beta}=108.1^{\circ}$. We solved the phage problem by molecular replacement using the structure of HslU from Haemophilus influenzae as a search model. The cell content analysis with this molecular replacement solution revealed that 24 molecules are contained in the asymmetric unit. This structure provides insight into the structural and mechanistic difference of the HslUV complex of gram-positive bacteria.

• Journal of Soil and Groundwater Environment
• /
• v.26 no.4
• /
• pp.20-26
• /
• 2021

In this work, an indigenous microbial consortium was obtained by selectively cultivating microbes using a long-aged petroleum-contaminated soil (Kuwait) containing recalcitrant petroleum hydrocarbons. The obtained microbial consortium was able to grow on and degrade the remaining petroleum hydrocarbons which could not have been utilized by the indigenous microbes in the original Kuwait soil. The following microbial community analysis using 16S rRNA gene sequencing suggested that the enhanced degradation of the remaining recalcitrant petroleum hydrocarbons by the novel microbial consortium may have been attributed to the selected bacterial populations belonging to Bacillus, Burkholderia, Sphingobacterium, Lachnospiraceae, Prevotella, Haemophilus, Pseudomonas, and Neisseria.

• Korean Journal of Veterinary Service
• /
• v.47 no.3
• /
• pp.133-142
• /
• 2024

The purpose of this study was to investigate seroprevalence of porcine respiratory diseases including porcine reproductive and respiratory syndrome (PRRS), porcine circovirus-2 (PCV-2), Mycoplasma hyopneumonia (MH), Pasteurella multocisa A (PMA), Haemophilus parasuis (HP), Actinobacillus pleuropneumonia type 2 (APP2), and Actinobacillus pleuropneumonia type 5 (APP5) in Jeonbuk state by enzyme-linked immunosorbent assay (ELISA). Total 5488 samples collected from four breeding pig farms and 55 commercial pig farms were tested. The overall seroprevalence of PCV-2, APP2, APP5, PMA, and HP was higher in breeding pig farms than in commercial pig farms, with higher antibody positivity rate (more than 97%) in breeding pig farms. Seroprevalence of MH or PRRS were 68.4% and 48.7% or 79.4% and 58.2% in commercial pig farms or breeding pig farms, respectively. The overall seroprevalence of the porcine respiratory diseases tested in this study varied depending on the age group of pigs, with the 40-day-old pig group showing the lowest seroprevalence and mean S/P titer ratio.

• Pediatric Infection and Vaccine
• /
• v.13 no.2
• /
• pp.163-173
• /
• 2006

Purpose : To reduce the number of injections necessary to vaccinate young infants, various combined vaccines have been developed. The $Comvax^{TM}$ manufactured by Merck & Co. is a combination of Hepatitis B and PRP-OMP conjugate Haemophilus influenzae Type b vaccine. The purpose of this study is to evaluate the immunogenicity and safety of $Comvax^{TM}$ in Korean infants. Methods : The infants who were vaccinated at 0 months of age with Hepatitis B vaccine, were recruited for this study after parental informed consent was obtained. The subjects were vaccinated with $Comvax^{TM}$ at 2 and 4 months of age. At each visit, infants were also immunized with DTaP, inactivated poliovirus vaccine, and pneumococcal vaccine when indicated. The serum anti-PRP and anti-HBs were measured at 2 months after the 1st dose(4 months age), and the 2nd dose(6 months age) by the ELISA and chemiluminescent microparticle immunoassay method, respectively. The local and systemic adverse reactions of vaccination were monitored for 3 consecutive days after each immunization. Results : Among sixty-five healthy infants(35 male infants) enrolled in this study; fifty eight(32 male infants) completed the scheduled immunizations. The geometric mean titers (GMTs) of anti-PRP at 2 months after the 1st dose and the 2nd dose were 1.96 ${\mu}g/mL$ (95% CI; 1.38~2.78) and 10.02 ${\mu}g/mL$ (95% CI; 7.04~14.26), respectively. Anti-PRP ${\geq}1.0$ ${\mu}g/mL$, was obtained in 63.2%(95% CI; 53.75~72.65) after 1 dose, and 96.6%(95% CI; 93.05~100) after 2 doses. The GMTs of anti-HBs were 38.32 mIU/mL(95% CI; 22.42~65.51), and 101.17 mIU/mL(95% CI; 65.94~155.25) at 2 month after the 1st dose and 2nd dose of $Comvax^{TM}$, respectively. Anti-HBs ${\geq}10$ mIU/mL was observed in 73.7%(95% CI; 65.07~82.33) after 1 dose and 94.8%(95% CI; 90.45~99.15) after 2 doses. Most of the adverse reactions after vaccination were mild. Irritability, the most common systemic reaction, was observed in 24.8%, followed by drowsiness(19.2%), poor feeding(19.2%) and fever(7.2%). Among the local reactions tenderness was observed in 25.6%, redness(${\geq}5$ mm) in 19.2% and swelling(${\geq}5$ mm) in 4.8%. Conclusion : The $Comvax^{TM}$ vaccine was highly immunogenic for PRP and safe in Korean infants. Although the hepatitis B vaccine component was administered at 0, 2, 4 months, this study showed good immunogenicity against HBsAg.

• Korean Journal of Veterinary Service
• /
• v.14 no.2
• /
• pp.159-174
• /
• 1991

A field trial of norfloxacin on bovine 206, swine 222 and poultry 205 with respiratory diseases and diarrhea was conducted from Sept 1, 1990 to Jan 30, 1991 in Inchon and Kyonggi-do. The results are as follows. 1. Guinea pigs and rabbits were dosages 10 and 20 times normal. Ten days of observation saw no side effect. 2. Oral treatment on bovine, swine and poultry showed a curing rate of 82.00∼89.06%(Mean 86.00%), compared with 87.27∼96.36%(Mean 92.24%) by Injection. 3. The curing rate was 81.92% by the fourth treatment. 4. The curing rate with and without the use of adjuvant was 80.00∼100% and 83.60∼93. 10%, respectively, for swine, and 81.82∼100% and 82.00∼97.14% for bovine. 5. The curing rate was more dependent on seriousness of illness, environment and time than age. 6. The main disease causing bacteria of bovine respiratory diseases： Haemolytic Sta 27.62%, Haemolytic Str 33.33%, sum of this bacteria is 60.95%, diarrhea: Haemolytic coliform 80.20%, swine respiratory diseases； Haemophilus Spp 20.95%, Haemolytic Sta 72%, Haemolytic Str 21.90%, Sum of these bacteria is 68.57％, diarrhea; Haemolytic coliform 57.26%, poultry respiratory diseases； mycoplasma Spp 29.52%, Haemolytic Sta 13.33％, Sum of this bacteria is 42.85%, diarrhea； Haemolytic coliform 53.00%. 7. The curing rate of norfloxacin by species of strain, the unidentified bacteria on bovine respiratory diseases was the lowest with 77.78％, the others ranged from 84.21％ to 100％ with most of them over 90%. 8. The loss of clinical sign on bovine and swine was the highest when after 2∼4 application. 9. In terms of antibiotic sensitivity test, norfloxacin was the highest with 84.62∼100％ (mean 90.09％) among eight bacterias, only 5 of 15 antibiotics had a sensitivity of over 56.25%, showing a high degree of tolerance.

• Clinical and Experimental Pediatrics
• /
• v.56 no.6
• /
• pp.231-234
• /
• 2013

This article contains the recommended immunization schedule by the Committee on Infectious Diseases of the Korean Pediatric Society, updated in March 2013, when Haemophilus influenzae type b vaccine is now included in the National Immunization Program in Korea. It also includes catch-up immunization schedule for children and adolescents who are behind the recommended schedule. These schedules are a minor revision of the corresponding parts of Immunization Guideline, 7th edition, of the Korean Pediatric Society, released in 2012. Pediatricians should be aware of these schedules to provide adequate immunization to Korean children and adolescents.

• Clinical and Experimental Pediatrics
• /
• v.59 no.12
• /
• pp.461-465
• /
• 2016

This report includes the recommended immunization schedule table for children and adolescents based on the 8th (2015) and revised 7th (2012) Immunization Guidelines released by the Committee on Infectious Diseases of the Korean Pediatric Society (KPS). Notable revised recommendations include: reorganization of the immunization table with a list of vaccines on the vertical axis and the corresponding age on the horizontal axis; reflecting the inclusion of Haemophilus influenzae type b vaccine, pneumococcal conjugate vaccine, and hepatitis A vaccine into the National Immunization Program since 2012; addition of general recommendations for 2 new Japanese encephalitis (JE) vaccines and their interchangeability with existing JE vaccines; addition of general recommendations for quadrivalent meningococcal conjugate vaccines and scope of the recommended targets for vaccination; and emphasizing catch-up immunization of Tdap vaccine. Detailed recommendations for each vaccine may be obtained from the full KPS 8th Immunization Guidelines.

• International Journal of Oral Biology
• /
• v.41 no.4
• /
• pp.199-208
• /
• 2016

The aim of this study was to identify the non-Aggregatibacter actinomycetemcomitans bacteria grown on the tryptic soy-serum-bacitracin-vancomycin (TSBV) medium, an A. actinomycetemcomitans selective medium. A total of 82 unidentified bacterial isolates from the oral cavities of a Korean population were kindly provide by the Korean Collection for Oral Microbiology. All the clinical isolates were grown on TSBV medium and bacterial DNA purified from each isolate was subjected to PCR with universal primers specific for bacterial 16S rRNA genes (16S rDNAs) sequence. The each bacterial 16S rDNA was amplified by PCR and the nucleotide sequences of it was determined by the dideoxynucleotide chain termination method. They were identified by 16S rDNA sequence comparison method at the specie-level. The data showed that Neisseria spp. (42 strains), Fusobacterium spp. (10 strains), Capnocytophaga spp. (8 strains), Propionibacterium acnes (5 strains), Aggregatibacter aprophilus (4 strains), Campylobacter spp. (5 strains), Veillonella dispar (3 strains), Streptococcus sp. (1 strain), Haemophilus parainfluenzae (1 strain), Leptotrichia wadei (1 strain), Morococcus sp./Neisseria sp. (1 strain), and Staphylococcus sp. (1 strain) were identified. These results could be used to develop a new A. actinomycetemcomitans-selective medium which is more effective than the TSBV medium in future studies.